Les fumeurs qui passent totalement de la cigarette classique à la e-cigarette ou vapotage, constatent une amélioration de leur santé respiratoire. Mais qu'en est-il pour ceux qui troquent seulement un ...

The webcast of the fireside chat will be accessible here and by visiting the "Events and Presentations" section of Fulcrum Therapeutics’ website at https://ir.fulcrumtx.com/events-and-presentations. A ...

Event: 15th Annual Craig-Hallum Alpha Select Conference Date: November 19, 2024 Location: Sheraton NY Times Square Hotel, New York, NY Format: 1x1 Meetings To request a meeting with Apyx, investors ...

Collaboration Revenue. Collaboration revenue was $0 for the three months ended September 30, 2024, compared to $26.7 million for the three months ended September 30, 2023. Revenues in 2023 were ...

Revenue: Revenue for the three months ended September 30, 2024, increased to approximately $1,958,000 compared to $397,000 for the same period one year ago. The increase is driven by the license ...

Cash, cash equivalents and marketable securities of $372.8 million, including $172.7 million equity raise in September, expected to provide runway into 2028 ...

Research and Development (R&D) Expenses: R&D expenses were $16.0 million for the three months ended September 30, 2024, as compared to $14.0 million for the same period in 2023. The increase was ...

WELLESLEY HILLS, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, ...

An audio webcast of the discussion will be available online at the OrthoPediatrics’ investor relations website, http://ir.orthopediatrics.com. Additionally, a replay will be available after the event.

Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and ...

For the quarter ended September 30, 2024, the Company had a loss from operations of $2.3 million, a 26% year-over-year improvement from $3.1 million for the comparable period of 2023, and a 9% ...

Announced collaboration agreements with Formosa Pharmaceuticals, Senju Pharmaceutical Co., Ltd. and SGN Nanopharma to develop novel therapeutics for use with Eyenovia’s Optejet® dispenser as potential ...